InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（1 笔）
内部人交易记录
董事已披露买入
2
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Lubner David Charles, 董事. Officer active across 4 companies, notably Arcellx, Inc.. Cumulatively, 8 filings have been recorded. Split: 2 buys · 1 sell. Total volume traded: €1.3m. History available since 8 February 2022. The latest transaction was disclosed on 7 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Lubner David Charles
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
55,555 股@ US$18.00100.0% 占其流量Common StockSEC:0001470831-26-000796:0
标准退出：2026年11月5日 (T+90)
53,625 股0Common StockSEC:0001193125-26-187601:0
21,659 股Common StockSEC:0001572000-26-000002:0
6,000 股@ US$6.287.7% 占其流量Common StockSEC:0001193125-26-017002:0
6,000 股@ US$75.0092.3% 占其流量Common StockSEC:0001193125-26-017002:1
35,400 股Common StockSEC:0001104659-23-129769:0
3,600 股@ US$6.85100.0% 占其流量Common StockSEC:0001104659-22-122395:0
标准退出：2023年2月21日 (T+90)
21,659 股0Common StockSEC:0001209191-22-008159:0
8 条申报中的 8 条
About Lubner David Charles
Lubner David Charles is Administrateur and has 8 filings in total. Among the recent filings available, they cover the period from 2022-02-09 to 2026-08-07, with EUR 891607 of buys and EUR 386627 of sells, including Braveheart Bio, Inc., Arcellx, Inc., POINT Biopharma Global Inc. and Dyne Therapeutics, Inc.
